Abstract
Objective: Locally advanced lung cancer has a poor prognosis, despite extensive surgery conducted in an effort to improve survival. We evaluated the safety and efficacy of induction therapy prior to extensive surgery for locally advanced lung cancer. Methods: Primary resection for lung cancer was done in 549 consecutive patients divided into three groups; 446 undergoing standard pulmonary resection (no extensive surgery), 87 undergoing extensive surgery without induction therapy, and 16 undergoing surgery after induction therapy. Results: Morbidity was 23.5%, 28.6%, and 43.8%, respectively. The rate was significantly higher in the induction group compared with the no extensive surgery group (P < 0.05). Surgical mortality was 0.67%, 3.4%, and 6.3%, respectively. The difference was statistically significant between the no extensive surgery and extensive surgery groups (P < 0.02), and between the no extensive surgery and induction groups (P < 0.02). Hospital mortality was 2.2%, 9.2%, and 6.3%, respectively. The rates were significantly higher in the extensive surgery (P < 0.01) and induction (P < 0.05) groups compared to the no extensive surgery group. Five-year survival was 50.3% for the patients who received induction therapy, and 14.7% for the patients who did not receive induction therapy. Conclusions: Survival differences between the induction and non induction groups were not significant, but some patients with T3 or T4 disease may benefit from induction therapy. The high morbidity of induction treatment should be recognized, and strict candidate selection and careful postoperative care used to help prevent increased mortality.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ginsberg RJ. Neoadjuvant (induction) treatment for non-small cell lung cancer. Lung Cancer 1995; 12: S33–40.
Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673–80.
Rosell R, Gomez-Codina J, Camps C, Madstre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in patients with non-small-cell lung cancer. New Eng J Med 1994; 330: 153–8.
Pass HI, Pgrebniak HW, Steinberger SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992; 55: 1365–74.
Roth JA, Atkinson EN, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1–6.
Kris MG, Pisters KMW, Ginsberg RJ, Rigas JR, Miller VA, Grant SC, et al. Effectiveness and toxicity of preoperative therapy in stage IIIA non-small-cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (clinical N2). Lung Cancer 1995; 12: S47–57.
Niwa H, Yamakawa Y, Kondo K, Kiriyama M, Kondo S, Ninoyu K, et al. Long-term follow-up after extensive surgery for advanced lung cancer. J Jap Assoc for Chest Surg 1994; 8: 697–704.
Niwa H, Masaoka A, Yamakawa Y, Fukai I, Kiriyama M. Surgical therapy for apical invasive lung cancer: different approaches according to tumor location. Lung Cancer 1993; 10: 63–71.
Niwa H, Yamakawa Y, Urakami T, Iizuka M, Fukai I, Kiriyama M, et al. Combined resection of left atrium for lung cancer, J Jap Assoc for Chest Surg 1992; 6: 10–15.
Mathisen DJ, Grillo HC. Carinal resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg 1991; 102: 16–23.
Allen MS, Mathisen DJ, Grillo HC, Wain JC, Moncure AC, Hilgenberg AD. Bronchogenic carcinoma with chest wall invasion. Ann Thorac Surg 1991; 51: 948–51.
Dartevelle PG, Chapelier AR, Pastorino U, Corbi P, Lenot B, Cerrina J, et al. Long-term follow-up after prosthetic replacement of the superior vena cava combined with resection of mediastinal-pulmonary malignant tumors. J Thorac Cardiovasc Surg 1991; 102: 259–65.
Tsuchiya R, Goya T, Naruke T, Suemasu K. Resection of tracheal carina for lung cancer. J Thorac Cardiovasc Surg 1990; 99: 779–87.
Mathisen DJ, Wain JC, Wright C, Choi N, Carey R, Hilgenberg AD, et al. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg 1996; 111: 123–33.
Fowler WC, Langer CJ, Curran WJ Jr, Keller SM. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993; 55: 986–9.
Rendina EA, Venuta F, Giacomo TD, Flaishman I, Fazi P, Ricci C, Rush VW. Safety and efficacy of bronchovascular reconstruction after induction chemotherapy for lung cancer. J Thorac Cardiovasc Surg 1997; 114: 830–7.
Cohen M, Hill CA, Cangir A, Sullivan MP. Thymic rebound after treatment of childhood tumors. AJR 1980; 135: 151–6.
Shin MS, Ho KJ. Diffuse thymic hyperplasia following chemotherapy for nodular sclerosing Hodgkin’s disease. An immunologic rebound phenomenon? Cancer 1983; 51: 30–3.
Tartas NE, Korin J, Dengra CS, Barazzutti LM, Blassentti A, Avalos JCS. Diffuse thymic enlargement in Hodgkin’s disease. JAMA 1985; 254: 406.
Author information
Authors and Affiliations
Additional information
Read at the Fifty-first Annual Meeting of The Japanese Association for Thoracic Surgery, Symposium, Tokyo, October 2–4, 1998.
Rights and permissions
About this article
Cite this article
Niwa, H., Nakamae, K., Yamada, T. et al. Assessment of extensive surgery for locally advanced lung cancer. Jpn J Thorac Caridovasc Surg 47, 411–418 (1999). https://doi.org/10.1007/BF03218036
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03218036